StockData
Northwest Biotherapeutics Inc logo

Northwest Biotherapeutics Inc (NWBO) stock

NWBOOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.16−0.00 (-0.88%)

Close on Oct 19, 2026Market cap $254.79MP/E –Yield –

Northwest Biotherapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Northwest Biotherapeutics's profit margin for the twelve months ending Jun 30, 2026 was -1736.4%. For fiscal 2025 it was -4365.9%, against -6062.1% the year before. The highest annual figure on record is 17823.5% in fiscal 2021.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-4365.9%+1696.2
FY2024Dec 31, 2024-6062.1%−2822.0
FY2023Dec 31, 2023-3240.1%+3000.6
FY2022Dec 31, 2022-6240.8%−24064.2
FY2021Dec 31, 202117823.5%+58863.1
FY2020Dec 31, 2020-41039.6%−40176.0
FY2019Dec 31, 2019-863.6%+7824.3
FY2018Dec 31, 2018-8687.9%+13080.9
FY2017Dec 31, 2017-21768.8%−8893.3
FY2016Dec 31, 2016-12875.4%−6277.3
FY2015Dec 31, 2015-6598.1%+2730.2
FY2014Dec 31, 2014-9328.3%−1196.2
FY2013Dec 31, 2013-8132.1%+588.1
FY2012Dec 31, 2012-8720.2%+319579.8
FY2011Dec 31, 2011-328300.0%−54620.0
FY2010Dec 31, 2010-273680.0%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-1142.6%+10596.3
Q1 FY2026Mar 31, 2026-621.3%+4536.9
Q4 FY2025Dec 31, 2025206.5%+12424.3
Q3 FY2025Sep 30, 2025-13414.5%−7987.6
Q2 FY2025Jun 30, 2025-11738.9%−8235.2
Q1 FY2025Mar 31, 2025-5158.1%+1289.8
Q4 FY2024Dec 31, 2024-12217.7%−9076.9
Q3 FY2024Sep 30, 2024-5426.9%+366.7
Q2 FY2024Jun 30, 2024-3503.7%+3684.3
Q1 FY2024Mar 31, 2024-6447.9%−5237.4
Q4 FY2023Dec 31, 2023-3140.9%+1599.1
Q3 FY2023Sep 30, 2023-5793.6%+10154.0
Q2 FY2023Jun 30, 2023-7188.1%−968.4
Q1 FY2023Mar 31, 2023-1210.5%+2316.6
Q4 FY2022Dec 31, 2022-4740.0%−17745.5
Q3 FY2022Sep 30, 2022-15947.6%+39777.9
Q2 FY2022Jun 30, 2022-6219.7%+83639.6
Q1 FY2022Mar 31, 2022-3527.0%+2899073.0
Q3 FY2021Sep 30, 202113005.4%+12544.7
Q4 FY2020Dec 31, 2020-55725.4%−56455.1
Q3 FY2020Sep 30, 2020-89859.3%−88784.9
Q2 FY2020Jun 30, 2020-2902600.0%−2902637.7
Q1 FY2020Mar 31, 2020460.7%+6639.5
Q4 FY2019Dec 31, 2019729.7%−2046.9
Q3 FY2019Sep 30, 2019-1074.4%+6543.3
Q2 FY2019Jun 30, 201937.7%+16359.7
Q1 FY2019Mar 31, 2019-6178.8%+78193.1
Q3 FY2018Sep 30, 20182776.6%+46024.5
Q2 FY2018Jun 30, 2018-7617.6%+10764.1
Q1 FY2018Mar 31, 2018-16322.0%−7293.3
Q4 FY2017Dec 31, 2017-84371.9%−81784.6
Q4 FY2016Dec 31, 2016-43247.9%−40457.9
Q3 FY2016Sep 30, 2016-18381.8%–
Q2 FY2016Jun 30, 2016-9028.7%–
Q1 FY2016Mar 31, 2016-2587.3%–
Q4 FY2015Dec 31, 2015-2790.0%–

More Northwest Biotherapeutics figures

See a number that looks wrong?